Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor;Activité clinique du CCI779 (temsirolimus), inhibiteur de mTOR

Bulletin du Cancer

Volumn 93, Issue 11, 2006, Pages 1139-1143

  Mounier, Nicolas ^a   Vignot, Stéphane ^b   Spano, Jean Philippe ^c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

mTor; Rapamycin; Temsirolimus

Indexed keywords

CYCLIN D; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TEMSIROLIMUS;

AREA UNDER THE CURVE; BREAST CANCER; CARCINOGENESIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MANTLE CELL LYMPHOMA; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN D1; GLIOBLASTOMA; HUMANS; KIDNEY NEOPLASMS; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS;

EID: 33845947046     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0152     Document Type: Review

References (25)

1. Alexandre J, Raymond E, Armand JP. Rapamycine et CCI779. Bull Cancer 1999; 86: 808-11.
2. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-37.
3. Cortot A, Armand JP, Soria JC. PI3K-AKT-mTOR pathway inhibitors. Bull Cancer 2006; 93: 19-26.
4. Pende M. mTOR, Akt, S6 kinases and the control of skeletal muscle growth. Bull Cancer 2006; 93: E39-43.
5. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-58.
6. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Pettersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9.
7. Dancey JE. mTOR inhibitors in hematologic malignancies. Clin Adv Hematol Oncol 2003; 1: 419-23.
8. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17: 487-94.
9. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-47.
10. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294-304.
11. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314-22.
12. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-24.
13. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
14. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18.
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) (abst LB4A). J Clin Oncol 2006; 24: 4.
16. Axelson J, Lindell M, Horlin K, Ohlsson B. Inhibition of different intracellular signal cascades in human pancreatic cancer cells. Pancreatol 2005; 5: 251-8.
17. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-31.
18. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005; 4: 25.
19. Okuno S, Mahoney M, Bailey H, Adkins D, Maples WJ, Ettinger D, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissues sarcoma. J Clin Oncol 2006; 24: 521; (abstr 9504).
20. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-56.
21. Ansell SM, Geyer SM, Kurtin P, Inwards DJ, Kaufmann SH, Flynn PJ, et al. Anti tumor activity of mTOR inhibitor temsirolimus tor relapsed mantle cell lymphoma: a phase 2 trial in the North Central cancer Treatment Group. J Clin Oncol 2006; 24: 430S; (abstr 7532).
22. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-75.
23. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, et al. In vivo anti-tumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004; 104: 4181-7.
24. Farag S, Zhang S, Miller M, Buckner M, Kraut E, Chan K, et al. Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results. J Clin Oncol 2006; 24: 450; (abstr 7616).
25. Vignot S, Besse B, Soria JC, Milano G, Spano JP. EGFR-targeted therapies: what's new? Bull Cancer 2006; 93: 13-8.